Stock Track | Krystal Biotech Soars 5.06% Intraday on FDA's RMAT Designation for KB707 Lung Cancer Therapy

Stock Track

3 hours ago

Krystal Biotech Inc. (KRYS) saw its stock price soar 5.06% during intraday trading on Monday.

The surge appears to be driven by news that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's KB707 therapy for advanced non-small cell lung cancer. This designation recognizes early clinical signals and is intended to support an expedited development and review path for the therapy.

The RMAT status for KB707 represents a significant regulatory milestone for Krystal Biotech as it seeks to expand its gene therapy platform beyond rare dermatology diseases into the competitive oncology market. This development could potentially accelerate the therapy's path to market and diversify the company's revenue streams beyond its current flagship product VYJUVEK.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1145538398"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145538398\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145538398?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145538398","market":"hk","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Soars 5.06% Intraday on FDA's RMAT Designation for KB707 Lung Cancer Therapy","media":"Stock Track","content":"<p>Krystal Biotech Inc. (KRYS) saw its stock price soar 5.06% during intraday trading on Monday.</p><p>The surge appears to be driven by news that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's KB707 therapy for advanced non-small cell lung cancer. This designation recognizes early clinical signals and is intended to support an expedited development and review path for the therapy.</p><p>The RMAT status for KB707 represents a significant regulatory milestone for Krystal Biotech as it seeks to expand its gene therapy platform beyond rare dermatology diseases into the competitive oncology market. This development could potentially accelerate the therapy's path to market and diversify the company's revenue streams beyond its current flagship product VYJUVEK.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Soars 5.06% Intraday on FDA's RMAT Designation for KB707 Lung Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Soars 5.06% Intraday on FDA's RMAT Designation for KB707 Lung Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Krystal Biotech Inc. (KRYS) saw its stock price soar 5.06% during intraday trading on Monday.</p><p>The surge appears to be driven by news that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's KB707 therapy for advanced non-small cell lung cancer. This designation recognizes early clinical signals and is intended to support an expedited development and review path for the therapy.</p><p>The RMAT status for KB707 represents a significant regulatory milestone for Krystal Biotech as it seeks to expand its gene therapy platform beyond rare dermatology diseases into the competitive oncology market. This development could potentially accelerate the therapy's path to market and diversify the company's revenue streams beyond its current flagship product VYJUVEK.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1145538398","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145538398","pubTimestamp":1771880442,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Krystal Biotech Inc. (KRYS) saw its stock price soar 5.06% during intraday trading on Monday.The surge appears to be driven by news that the U.S. Food and Drug Administration (FDA) has granted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"个股追踪|Krystal Biotech盘中大涨5.06%因FDA授予KB707肺癌疗法RMAT资格","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Krystal Biotech Inc. (KRYS) saw its stock price soar 5.06% during intraday trading on Monday.The surge appears to be driven by news that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's KB707 therapy for advanced non-small cell lung cancer. This designation recognizes early clinical signals and is intended to support an expedited development and review path for the therapy.The RMAT status for KB707 represents a significant regulatory milestone for Krystal Biotech as it seeks to expand its gene therapy platform beyond rare dermatology diseases into the competitive oncology market. This development could potentially accelerate the therapy's path to market and diversify the company's revenue streams beyond its current flagship product VYJUVEK.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}